The FDA approved Eli Lilly's monoclonal antibody Taltz for the treatment of active ankylosing spondylitis in adults, reports Pharmaceutical Business Review.
Four things to know:
1. Ankylosing spondylitis, also known as radiographic axial spondyloarthritis, affects the spine and pelvic joints.
2. Symptoms of the condition include chronic inflammatory back pain, stiffness as well as impaired mobility and function.
3. The Taltz injection was approved due to the efficacy and safety demonstrated in two randomized, double-blind phase 3 studies featuring 657 patients with ankylosing spondylitis.
4. This is the third FDA approval for Taltz. Previously it was approved for the treatment of adults with plaque psoriasis and for active psoriatic arthritis in adults.